UBA7

Summary: UBA7 localizes to the cytoplasm where it activates ISG15 and modifies cytoplasmic substrates. This localization is supported by extensive experimental evidence including immunofluorescence studies (PMID:29743376) and is essential for ISGylation of cytoplasmic antiviral proteins.

Reason: Core cellular component annotation with strong experimental support. UBA7 is indeed present in the cytoplasm where it performs ISG15 activation and modifies cytoplasmic proteins involved in antiviral defense.

Summary: UBA7 is the sole E1 enzyme for ISG15, catalyzing ATP-dependent ISG15 activation and thioester bond formation. This is the primary molecular function of UBA7, extensively validated through biochemical and genetic studies showing it specifically activates ISG15 but not ubiquitin in mammals.

Reason: This is the core molecular function of UBA7. Multiple studies demonstrate UBA7 (UBE1L) specifically activates ISG15 and transfers it to UBE2L6. Knockout mice lacking UBA7 cannot perform ISGylation and are highly susceptible to viral infections. Falcon deep research (2023-2024) reinforces that UBA7 is the dedicated, sole ISG15 E1, distinct from the ubiquitin E1 UBA1, with cryo-EM structures resolving its activation and E1->E2 transfer mechanism.

Summary: UBA7 initiates ISG15-protein conjugation (ISGylation) by activating ISG15 and transferring it to UBE2L6. This is the primary biological process mediated by UBA7, essential for antiviral immunity and protein regulation.

Reason: Core biological process annotation. UBA7 is absolutely required for ISGylation - it is the sole E1 enzyme that initiates the ISG15 conjugation cascade. This function is well-established through multiple experimental approaches.

Summary: UBA7-mediated ISGylation is a critical component of the innate immune response, particularly antiviral defense. UBA7 knockout mice are highly susceptible to viral infections, demonstrating its essential role in innate immunity.

Reason: Well-established role in innate immunity. UBA7 is an interferon-stimulated gene that enables ISGylation of antiviral proteins. Genetic ablation studies confirm its requirement for innate immune control of multiple viruses. Falcon deep research adds independent 2024 evidence that UBA7-dependent ISGylation supports cGAS-STING-driven antiviral gene expression and that UBA7 knockdown facilitates HSV-1 infection.

Summary: UBA7 participates in the DNA damage response through ISGylation of p53 and other DNA damage response factors. DNA damage induces UBA7 expression and subsequent ISGylation enhances p53 transactivation activity.

Reason: Valid annotation supported by literature. UBA7-mediated ISGylation of p53 occurs in response to DNA damage and modulates p53 activity, contributing to the cellular DNA damage response.

Summary: UBA7 is indeed a ubiquitin-like modifier activating enzyme, but this general term is less informative than the specific ISG15 activating enzyme activity (GO:0019782). UBA7 specifically activates ISG15, not other ubiquitin-like modifiers in mammals.

Reason: While technically correct, this annotation is too general. UBA7 specifically activates ISG15, not other ubiquitin-like modifiers. The more specific term GO:0019782 (ISG15 activating enzyme activity) better captures UBA7's molecular function.

Proposed replacements: ISG15 activating enzyme activity

Summary: UBA7 binds ATP for ISG15 adenylation, but this general nucleotide binding term is less informative than the specific ATP binding activity (GO:0005524) that is mechanistically required for ISG15 activation.

Reason: While UBA7 does bind nucleotides, specifically ATP is required for its enzymatic function. The more specific GO:0005524 (ATP binding) annotation is already present and more informative.

Proposed replacements: ATP binding

Summary: UBA7 requires ATP binding for ISG15 activation. The adenylation domain binds ATP to catalyze formation of the ISG15-adenylate intermediate, an essential step in the ISGylation cascade.

Reason: Core molecular function. ATP binding is mechanistically required for UBA7's E1 enzyme activity - it uses ATP to adenylate ISG15's C-terminus before thioester bond formation. This is well-documented in structural and biochemical studies.

Summary: UBA7 localizes to the nucleus/nucleoplasm where it can ISGylate nuclear proteins including p53 and other transcription factors. Both immunocytochemistry and functional studies support nuclear localization. Note that falcon deep research cautions that direct compartment-resolved localization data for UBA7 itself are limited in the recent (2023-2024) literature; the nuclear annotation is best supported by functional ISGylation of nuclear substrates (e.g., p53) rather than by primary localization imaging of UBA7.

Reason: Valid cellular component annotation but treated as non-core. UBA7 can be present in the nucleus where it modifies nuclear substrates like p53, and curated Reactome pathways place ISGylation of nuclear PCNA in the nucleoplasm. However, falcon deep research explicitly flags that direct localization data for UBA7 itself are limited, and the dominant, best-supported site of UBA7 catalysis is the cytosol. The nuclear annotation is therefore retained as a secondary location rather than a core one.

Summary: Cytoplasm localization is correct for UBA7. While this duplicates the IBA annotation, it provides additional computational support.

Reason: UBA7 localizes to the cytoplasm where it performs ISG15 activation. Multiple evidence codes supporting the same correct annotation provide additional confidence.

Summary: UBA7 has ligase activity as an E1 enzyme that catalyzes thioester bond formation with ISG15. However, the more specific term GO:0019782 (ISG15 activating enzyme activity) better describes its function.

Reason: While UBA7 does have ligase activity (forms thioester bonds), this term is too general. The specific ISG15 activating enzyme activity (GO:0019782) more accurately describes UBA7's molecular function.

Proposed replacements: ISG15 activating enzyme activity

Summary: Generic protein binding annotation from a large-scale interactome study. While UBA7 does interact with proteins (ISG15, UBE2L6), this uninformative term doesn't specify which proteins or the functional significance.

Reason: Protein binding is too generic and uninformative. UBA7 obviously binds proteins as part of its enzymatic function (ISG15, UBE2L6), but this annotation provides no useful functional information. The specific enzymatic activities are already captured in other annotations.

Summary: Another generic protein binding annotation. The referenced paper studies E1-E2 interactions, but the generic protein binding term doesn't capture the specific functional interactions.

Reason: Too generic and uninformative. While the paper studies E1-E2 charging mechanisms, the generic protein binding term adds no functional information beyond what's captured in the ISG15 activating enzyme activity annotation.

Summary: Generic protein binding from another interactome study. Provides no specific functional information about UBA7's enzymatic activities or biological roles.

Reason: Uninformative generic annotation. The specific protein interactions relevant to UBA7 function (with ISG15, UBE2L6) are better captured by the enzymatic activity annotations.

Summary: Generic protein binding from a reference interactome map. No specific functional information provided.

Reason: Generic and uninformative. UBA7's specific protein interactions that matter functionally are already captured in its enzymatic activity annotations.

Summary: Generic protein binding from a neurodegenerative disease interactome study. No specific functional relevance to UBA7's core activities.

Reason: Generic and uninformative annotation. The specific functionally relevant protein interactions for UBA7 are already captured in its enzymatic activity annotations.

Summary: Generic protein binding from a cell-specific interactome study. Provides no specific functional information about UBA7.

Reason: Uninformative generic annotation that doesn't specify which proteins or functional significance. UBA7's specific enzymatic interactions are already captured.

Summary: ISG15 activating enzyme activity is the core molecular function of UBA7. While this duplicates the IBA annotation, it provides additional computational support.

Reason: This is the primary molecular function of UBA7. Multiple evidence codes supporting the same correct annotation provide additional confidence.

Summary: UBA7-mediated ISGylation can lead to degradation of certain proteins (e.g., PML-RARα, cyclin D1), but this is an indirect downstream effect rather than UBA7's primary function.

Reason: Valid but non-core function. While ISGylation by UBA7 can target some proteins for degradation, this is a downstream consequence rather than the primary function. The core function is ISG15 activation and conjugation.

Summary: ISG15-protein conjugation is the core biological process mediated by UBA7. While this duplicates the IBA annotation, it provides additional computational support.

Reason: UBA7 initiates ISG15-protein conjugation as the sole E1 enzyme. Multiple evidence codes supporting the same correct annotation provide additional confidence.

Summary: This annotation is incorrect. UBA7 is an E1 activating enzyme, not an E2/E3 transferase. The paper actually studies E1-E2 interactions in ISGylation, not ubiquitin transfer. UBA7 activates ISG15, not ubiquitin.

Reason: Incorrect annotation. UBA7 is an E1 enzyme that activates ISG15, not an E2/E3 transferase. The term ubiquitin-protein transferase activity refers to E2/E3 enzymes. UBA7 should be annotated with ISG15 activating enzyme activity instead.

Proposed replacements: ISG15 activating enzyme activity

Summary: Incorrect annotation. The paper clearly identifies UBA7 (UbE1L) as the E1 enzyme for ISG15, not a transferase. UBA7 activates ISG15, it doesn't transfer ubiquitin.

Reason: Misannotation. The cited paper explicitly states UBA7/UbE1L is the ISG15 E1 activating enzyme, not an E2/E3 transferase. It should be annotated with ISG15 activating enzyme activity.

Proposed replacements: ISG15 activating enzyme activity

Summary: Incorrect process annotation. UBA7 mediates ISGylation (ISG15 conjugation), not ubiquitination. UBA7 is highly specific for ISG15 in mammals and does not activate ubiquitin.

Reason: Wrong process. UBA7 specifically mediates ISG15-protein conjugation (ISGylation), not protein ubiquitination. In mammals, UBA7 cannot activate ubiquitin, only ISG15.

Proposed replacements: ISG15-protein conjugation

Summary: Direct experimental evidence for cytoplasmic localization of UBA7 (UBE1L) through immunofluorescence and colocalization studies in the context of HCMV infection.

Reason: Strong experimental evidence for cytoplasmic localization. The paper demonstrates UBA7/UBE1L localization and its functional relevance in the cytoplasm.

Summary: Direct experimental evidence that UBA7 (UBE1L) mediates ISG15-protein conjugation, working with UbcH8 as the E2 enzyme in the ISGylation cascade.

Reason: Strong experimental evidence for UBA7's role in ISG15-protein conjugation. The paper directly demonstrates the E1-E2 cascade for ISGylation.

Summary: Experimental evidence showing UBA7 participates in ISG15-protein conjugation, working with HERC5 as the E3 ligase in the ISGylation pathway.

Reason: Direct experimental evidence for ISGylation. The paper demonstrates the complete ISGylation cascade including UBA7's role as the E1 enzyme.

Summary: Direct experimental evidence that UBA7-mediated ISGylation modulates type I interferon signaling and antiviral response during hepatitis E virus replication. Falcon deep research adds a 2024 CRISPR study in fallopian tube epithelial cells showing UBA7-null cells have blunted dsRNA (Poly I:C)-triggered NF-kB activation and reduced IFNB1 induction.

Reason: Strong experimental evidence for role in innate immunity. The paper directly demonstrates ISGylation's role in antiviral defense and interferon signaling.

Summary: Curated annotation from Reactome showing UBA7 localizes to nucleoplasm where it can ISGylate nuclear proteins including monoubiquitinated PCNA.

Reason: Valid cellular component annotation from curated Reactome pathway. UBA7 is present in the nucleoplasm where it modifies nuclear proteins. This is consistent with experimental evidence of nuclear localization.

Summary: Curated annotation from Reactome pathway 'Activation of ISG15 by UBA7 E1 ligase' showing cytosolic localization where ISG15 activation occurs. Falcon deep research independently supports cytosolic/intracellular ISGylation as the dominant site of UBA7 activity.

Reason: Valid cellular component annotation from curated Reactome pathway. UBA7 functions in the cytosol to activate ISG15. Multiple Reactome pathways consistently place UBA7 in the cytosol.

Summary: Curated annotation from Reactome pathway 'Transfer of ISG15 from E1 to E2 (UBCH8)' confirming cytosolic localization.

Reason: Valid annotation from curated pathway. Shows UBA7 in cytosol transferring ISG15 to the E2 enzyme UBE2L6/UBCH8.

Summary: Curated annotation from Reactome pathway 'ISGylation of DDX58' showing cytosolic localization for ISGylation of RIG-I.

Reason: Valid annotation showing UBA7 in cytosol for ISGylation of the antiviral sensor RIG-I/DDX58.

Summary: Another Reactome annotation for ISGylation of DDX58 (RIG-I) in cytosol. Multiple consistent cytosolic annotations from curated pathways.

Reason: Consistent with other curated annotations placing UBA7 in cytosol for ISGylation reactions.

Summary: Direct experimental demonstration that UBA7 (UBE1L) functions as the E1 activating enzyme for ISG15, forming thioester intermediates and transferring ISG15 to UbcH8.

Reason: Strong direct experimental evidence for ISG15 activating enzyme activity. The paper demonstrates UBA7/UBE1L activates ISG15 and transfers it to the E2 enzyme.

Summary: Direct experimental evidence that UBA7 mediates ISG15-protein conjugation, specifically showing ISG15 conjugation to UbcH6 and other substrates.

Reason: Strong experimental evidence for ISGylation. The paper directly demonstrates UBA7's essential role in ISG15-protein conjugation.

Summary: UBA7 is a canonical type I interferon-stimulated gene (ISG) that is robustly induced by type I interferon as part of the antiviral response program. The cited study characterizes UBA7 within a type I interferon-regulated gene network.

Reason: Direct regulation by type I interferon is a key aspect of UBA7 function not captured in existing annotations. Upon type I IFN treatment, UBA7 levels rise alongside ISG15. The cited reference (PMID:31974171) describes a type I interferon-regulated gene network, so the appropriate term is response to type I interferon (GO:0034340) rather than the type II (IFN-gamma) term.

Summary: ISGylation mediated by UBA7 can regulate interferon signaling in a negative feedback manner through modification of signaling proteins.

Reason: UBA7-mediated ISGylation modulates interferon signaling pathways, creating regulatory feedback loops in immune responses.

Summary: UBA7 functions as a tumor suppressor through ISGylation of key regulatory proteins including p53 and cell cycle regulators

Reason: UBA7 acts as a tumor suppressor that negatively regulates cell proliferation through multiple mechanisms. As the E1 enzyme for ISG15, UBA7 mediates ISGylation of critical tumor suppressor proteins including p53, enhancing their stability and activity. UBA7 is frequently downregulated in various cancers, and its loss promotes tumorigenesis. The protein also regulates cell cycle progression through ISGylation of cell cycle regulatory proteins, contributing to growth control and cancer prevention.

Summary: Essential component of antiviral immunity through ISG15 activation and ISGylation of antiviral effector proteins

Reason: UBA7 is the sole E1 activating enzyme for ISG15, making it essential for the ISGylation pathway that provides broad-spectrum antiviral defense. Upon viral infection or interferon stimulation, UBA7 activates ISG15 which then modifies hundreds of target proteins to establish an antiviral state. UBA7-mediated ISGylation directly targets viral proteins for degradation and enhances the activity of antiviral effectors. Loss of UBA7 function increases susceptibility to viral infections, demonstrating its critical role in host defense. Falcon deep research adds a concrete 2024 example of the UBA7->UBE2L6->HERC5 axis restricting SARS-CoV-2 by ISGylating the viral nucleocapsid (N) protein.